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Background: Pharmacokinetic interactions between rifampicin and protease inhibitors (PIs) complicate the
management of HIV-associated tuberculosis. Rifabutin is an alternative rifamycin, for patients requiring PIs. Recently
some international guidelines have recommended a higher dose of rifabutin (150 mg daily) in combination with
boosted lopinavir (LPV/r), than the previous dose of rifabutin (150 mg three times weekly {tiw}). But there are limited
pharmacokinetic data evaluating the higher dose of rifabutin in combination with LPV/r. Sub-optimal dosing can
lead to acquired rifamycin resistance (ARR). The plasma concentration of 25-O-desacetylrifabutin (d-RBT), the metabolite
of rifabutin, increases in the presence of PIs and may lead to toxicity.
Methods and results: Sixteen patients with TB-HIV co-infection received rifabutin 300 mg QD in combination with
tuberculosis chemotherapy (initially pyrazinamide, isoniazid and ethambutol then only isoniazid), and were then
randomized to receive isoniazid and LPV/r based ART with rifabutin 150 mg tiw or rifabutin 150 mg daily. The rifabutin
dose with ART was switched after 1 month. Serial rifabutin and d-RBT concentrations were measured after 4 weeks of
each treatment. The median AUC0–48 and Cmax of rifabutin in patients taking 150 mg rifabutin tiw was significantly
reduced compared to the other treatment arms. Geometric mean ratio (90% CI) for AUC0–48 and Cmax was
0.6 (0.5-0.7) and 0.5 (0.4-0.6) for RBT 150 mg tiw compared with RBT 300 mg and 0.4 (0.4-0.4) and 0.5 (0.5-0.6) for RBT
150 mg tiw compared with 150 mg daily. 86% of patients on the tiw rifabutin arm had an AUC0-24 < 4.5 μg.h/mL,
which has previously been associated with acquired rifamycin resistance (ARR). Plasma d-RBT concentrations
increased 5-fold with tiw rifabutin dosing and 15-fold with daily doses of rifabutin. Rifabutin was well tolerated at all
doses and there were no grade 4 laboratory toxicities. One case of uveitis (grade 4), occurred in a patient taking
rifabutin 300 mg daily prior to starting ART, and grade 3 neutropenia (asymptomatic) was reported in 4 patients.
These events were not associated with increases in rifabutin or metabolite concentrations.
Conclusions: A daily 150 mg dose of rifabutin in combination with LPV/r safely maintained rifabutin plasma
concentrations in line with those shown to prevent ARR.
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Treating HIV associated tuberculosis remains a formid-
able challenge. In 2014, 13% of the 9 million incident
cases of tuberculosis, and 25% of deaths from tubercu-
losis were in HIV-infected patients [1]. Combining
efavirenz-based first-line antiretroviral therapy (ART)
with rifampicin based tuberculosis chemotherapy signifi-
cantly reduces mortality in these patients [2-4] and is safe
and efficacious. However, as public sector ART expands
in developing countries, an increasing number of patients
are developing virological failure and require second-line
ART with protease inhibitors [5,6]. Combining rifampicin
and protease inhibitor-based second-line ART is prob-
lematic as rifampicin significantly reduces the bioavail-
ability and increases the clearance of protease inhibitors
by accelerating their metabolism via induction of cyto-
chrome 3A4 (CYP3A4) enzymes. Increasing the dose
of the protease inhibitor or co-administering higher doses
of a CYP3A4 inhibitor to ameliorate this adverse drug-
drug interaction have been thwarted by hepatotoxicity and
other problems with tolerability [7,8].
Rifabutin, a less potent inducer of CYP3A4 [9,10], is
recommended at 300 mg daily as prophylaxis and treat-
ment of Mycobacterium avium complex (MAC) and for
the treatment of drug susceptible tuberculosis. Plasma
concentrations of rifabutin are increased in the presence
of protease inhibitors [11] therefore dose adjustments
are recommended when rifabutin is combined with a
protease inhibitor. Some recent guidelines recommend
dosing rifabutin 150 mg daily (QD) in combination with
a ritonavir-boosted protease inhibitor [12], but others
still recommend 150 mg three time weekly (tiw) [13].
These differences in guidelines are due to the limited
pharmacokinetic studies comparing the 2 dosing regi-
mens of rifabutin and persisting concerns about the tol-
erability and toxicity of using higher doses of rifabutin
[14]. Previous reports suggested that less frequent dosing
at 150 mg in HIV-positive tuberculosis patients can result
in inadequate rifamycin concentrations [15,16], relapse
[17] and acquired rifamycin resistance (ARR) [18]. Patients
with rifabutin AUC0–24 < 4.5 μg.h/mL were identified as at
the highest risk of ARR. The optimum pharmacokinetic
parameter associated with treatment efficacy is unknown.
Elimination of rifabutin is primarily by metabolism via
various routes, with deacetylation to d-RBT considered
the most important. The d-RBT metabolite is known to
have antibacterial activity [19] but may also contribute
to toxicity, and is thought to be metabolized further in
the liver by CYP 3A4. The present study was therefore
undertaken to compare the bioavailability of rifabutin and
d-RBT after two different dosing regimens of rifabutin
(150 mg tiw and 150 mg daily) in combination with ritona-
vir boosted lopinavir (LPV/r), the protease inhibitor most
commonly used to treat HIV infection in South Africa.Methods
Study design
An open-label, randomized, three-period, crossover drug
interaction study was undertaken to investigate the
pharmacokinetics of rifabutin with and without PI-based
ART (Figure 1). The secondary objective was to assess
the tolerability and safety of rifabutin and LPV/r. The
Biomedical Research Ethics Committees of the Univer-
sities of Kwa-Zulu Natal and Cape Town, and the Ethics
Committee of the International Union against Tubercu-
losis and Lung Disease (Paris) and the South African
Medicines Control Council approved the study. The trial
registration number was NCT00640887 (https://clinical-
trials.gov/).
Recruitment
Patients were recruited from local tuberculosis clinics
in Kwa-Zulu Natal, South Africa. The study ran from
February 2009 until October 2010. All patients provided
written informed consent. Eligibility requirements were
a diagnosis of pulmonary tuberculosis confirmed by mi-
croscopy or culture, HIV infection with CD4 lymphocyte
count ≥50 and ≤200 cells/mm3, weight ≥50 kg or a
BMI ≥18, a Karnofsky score Q ≥80% and no grade 3 or 4
clinical or laboratory findings according to DAIDS tables
[20]. The CD4 restrictions for this study were a reflection
of the South African guidelines for the initiation of ART
in TB patients at the time the study was conducted [21].
Patients with CD4 counts below 50 were recommended
to initiate therapy immediately whereas those with CD4
count between 50 and 200 were initiated at 2 months of
TB therapy.
Only patients who completed and adhered to 6 weeks
of standard intensive phase chemotherapy and had not
received ART therapy in the preceding three months
were enrolled. Patients with a previous tuberculosis epi-
sode within three years prior to the current episode, a
history of prior treatment for MDR tuberculosis, con-
comitant opportunistic infection requiring additional anti-
microbial treatment, a formal contraindication to any trial
medication, diabetes mellitus requiring treatment, recre-
ational drug or alcohol abuse, mental illness, total neutro-
phil count <1200 cells/L, hemoglobin <6.8 g/dL, or liver
function tests > grade 2, pregnancy or lactating women
were excluded.
Treatments under study
At enrollment, six weeks after starting standard tubercu-
losis chemotherapy, rifampicin was switched to rifabutin
300 mg daily (Figure 1). After two weeks of rifabutin,
pyrazinamide and ethambutol were stopped and patients
continued with daily doses of rifabutin 300 mg in com-
bination with isoniazid 300 mg. After two more weeks,
the first pharmacokinetic evaluation (PK1) was carried
Figure 1 Diagram showing the timings of clinical trial visits and study regimens to tuberculosis (TB) treatment. Patients were screened
after 5 weeks of standard TB chemotherapy administered as a fixed dose combination (Rmp – rifampicin, Inh – isoniazid, Pza – pyrazinamide,
Emb – ethambutol). If patients met all eligibility criteria they were enrolled after 6 weeks of TB chemotherapy and switched to rifabutin 300 mg
daily in place of rifampicin. At the end of the intensive phase (8 weeks of TB treatment) they continued with rifabutin 300 mg daily and isoniazid
300 mg daily. This was followed by the first pharmacokinetic visit (PK1) at which the bioavailability of rifabutin in the absence of LPV/r was
assessed. The patients then initiated antiretroviral therapy (ART) and altered their dose of rifabutin based on the randomization to either 150 mg
tiw of 150 mg daily. After a month of ART a second pharmacokinetic evaluation (PK2) was completed. Patients then switched doses of rifabutin
from 150 mg tiw to daily, or vice versa, and after a further month of treatment a third pharmacokinetic evaluation was completed (PK3). Patients
then continued with rifabutin at the dose they were on at PK3, in combination with ART and isoniazid until a total of 24 weeks of TB treatment
had been completed. Patients continued ART after stopping TB treatment.
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ent rifabutin dose sequences together with daily doses of
isoniazid and ART comprising LPV/r (400/100 mg) plus
lamivudine (150 mg bd) and stavudine (30 mg bd). Half
the patients received rifabutin 150 mg tiw for 4 weeks
before being switched to rifabutin 150 mg daily after a
second pharmacokinetic evaluation (PK2). A third phar-
macokinetic evaluation (PK3) took place after 4 weeks
and they remained on this dose of rifabutin until com-
pletion of tuberculosis treatment. Half the patients re-
ceived the two rifabutin doses in a reverse sequence.
Physical examinations and laboratory investigations were
done at screening, after 1 month of rifabutin (trial day
28 – PK1), after 1 month of ART and rifabutin (trial
day 56 – PK2), after 2 months of ART and rifabutin
(trial day 84 – PK2) and 2 weeks before the end of TB
treatment (trial day 112) as shown in Figure 1. Upon com-
pletion of the trial, patients were referred to local antiretro-
viral clinics for further management. Pfizer (South Africa)
supplied the rifabutin (Mycobutin®) 150 mg capsules and
the new film-coated tablet formulation of LPV/r, Aluvia®
was purchased from Abbott Laboratories (USA).
Sample size
Based on the AUC0–24 for rifabutin determined in previ-
ous studies, it was estimated that a sample size of 12participants had a power of 80% to detect a 20% differ-
ence between the mean AUC0–24 for rifabutin with and
without ART. The sample size was calculated on the as-
sumption that 16 enrolled participants would result in a
minimum of 12 evaluable subjects. The additional 4 pa-
tients in each arm were recruited as it was thought that
there may be drop out of patients before completing 3
full pharmacokinetic visits.
Pharmacokinetic sampling
All patients were admitted before each pharmacokinetic
occasion and were fasted from midnight. A standard
hospital breakfast (oats with 2 slices of toast and tea)
was served 2 h after drug ingestion. Blood draws were
done at 0, 2, 3, 4, 5, 6, 8, 12, 24 and 48 h after drug in-
gestion. The samples were placed on ice immediately
and centrifuged at 3000 rpm at 4°C for 10 minutes. Sep-
arated plasma was stored immediately at −70°C until
batch analysis.
Drug analyses
Rifabutin and d-RBT were analyzed with a validated LC/
MS/MS assay [14]. Rifaximin was used as internal stand-
ard at a concentration of 100 ng/ml. Gradient chroma-
tography was performed on a Phenomenex, Luna 5 μm
PFP (2), 100 A, 50 mm× 2 mm analytical column, using
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flow rate of 500 μl/min. An AB Sciex API 3200 mass
spectrometer monitored protonated ions at m/z 847.4 to
the product ions at m/z 95.1 for rifabutin, at m/z 805.4
to the product ions at m/z 95.1 for d-RBT, and at m/z
786.3 to the product ions m/z 151.1 for rifaximin. Rifa-
butin and d-RBT accuracies were between 99.1% and
109.0% during inter-batch validation. The co-efficient of
variation during inter-batch validation was less than
9.2%. The calibration range for rifabutin was between
3.91 ng/ml and 1000 ng/ml, and for d-RBT between
0.780 ng/ml and 200 ng/ml. The intra- and inter-batch
accuracy statistics of the rifabutin and d-RBT assay val-
idation were between 93.3% and 111.5%, and between
99.1% and 109%. The co-efficient of variation was less
than 13.8%.
Plasma lopinavir concentrations were quantified by a
validated LCMS/MS method previously described by Chi
et al. [22]. The calibration curve was linear over the
range from 0.05 to 20 mg/L. Samples with a concentra-
tion of >20 mg/L, were diluted and re-analyzed. Any
sample below the LLQ was reported as 0.5 X LLQ for
analysis. The intra- and inter-batch accuracy statistics of
the lopinavir assay validation were between 95.0% and
96.4%, and between 96.2% and 99.1%. The coefficient of
variation (%CV) was less than 3.9%.
Pharmacokinetic analysis
The main pharmacokinetic measures for rifabutin, d-RBT
and lopinavir were derived by non-compartmental analysis
using Stata (StataCorp. 2009. Stata Statistical Software:
Release 11. College Station, TX: StataCorp LP). The peak
concentration (Cmax), and time to Cmax (Tmax) were ob-
tained directly from concentration-time profiles. Drug con-
centrations at the end of a dosing interval are reported as
Cmin and pre-dose concentrations as C0. The steady-state
AUC from time 0 h to the last quantifiable sample at 24 h
(AUC0–24) or 48 h (AUC0–48) for rifabutin and 12 h
(AUC0–12) for LPV/r were calculated by the linear trapez-
oidal method. The apparent total oral clearance of rifa-
butin from plasma at steady state (CL/F) was calculated
by dose/AUC.
Statistics
For statistical analysis, the AUC0–24 was log-transformed.
A linear mixed model with two doses (high and low), day
(2 and 3), the sequence of the doses, log AUC0–24 and id
nested within sequence was used. As there was no signifi-
cant effect of sequencing of the doses (whether the patients
received the tiw dose before the daily dose of rifabutin or
vice versa), the two corresponding doses from each arm
were pooled for further analysis. A paired t-test was used
to compare the AUC0–24 for the 150 mg daily dose with
that for 150 mg tiw and 300 mg daily doses. An AUC0–48was derived for the 150 mg daily and 300 mg daily doses
by doubling the AUC0–24. This was compared with the
AUC0–48 for the 150 mg tiw dose using a paired t-test.
The dosing interval is 48 hours for the tiw dose for 2
of 3 doses.
To calculate geometric mean ratios (GMR) for AUC,
log means and 90% confidence limits were back trans-
formed and presented in their original units as geometric
means. Geometric mean ratios for the AUC of rifabutin:
150 mg daily with LPV/r / 300 mg daily, and 150 mg tiw
with LPV/300 mg daily, respectively, were computed.
A P-value < 0.05 was considered significant. Inter-patient
variability was measured by co-efficient of variation (%CV)
that was calculated as {100 X (e (var est) -1)1/2}. Baseline




Sixteen patients received LPV/r therapy with rifabutin.
Two patients were prematurely withdrawn from the study
and were therefore not evaluable for pharmacokinetic
analysis, one due to uveitis and another due to non-
compliance with trial medication. All patients were Black
South Africans and (64%) were male. All patients had not
previously received any antiretroviral therapy. The evalu-
able subjects’ mean (SD) age was 31.5 (5.8) years, weight
was 59.9 (9.7) kg, height was 160 (7.7) cm, BMI was
23.3 (2.6), Karnofsky score Q was 100% (100) and CD4+
lymphocyte count was 150.9 (12.1) cells/mm3.
Rifabutin and 25-O-desacetylrifabutin pharmacokinetic
analysis
The main pharmacokinetic parameters for rifabutin and
d-RBT are summarized in Table 1 and shown graphically
in Figures 2 and 3. The AUC0–24 of rifabutin 150 mg
daily with LPV/r was significantly higher when com-
pared to the AUC0–24 of rifabutin 300 mg daily in the
absence of LPV/r (p = 0.004). In contrast, the AUC0–48 of
rifabutin 150 mg tiw with LPV/r was significantly lower
than the AUC0–48 of rifabutin 300 mg daily (p = 0.0001).
These differences were large as demonstrated by the
GMR (Table 2). The GMR (90% CI) for AUC0–48 was
0.6 (0.5-0.7) and 0.5 (0.4-0.6) for rifabutin 150 mg tiw
compared with rifabutin 300 mg. For the comparison of
the 150 mg daily dose of rifabutin with the 300 mg dose
the GMR of the AUC0–24 was 1.6 (1.4-1.9). Wide inter-
patient variability was observed in rifabutin AUC for all
three doses (Table 2). The %CV was 24% for the 300 mg
dose, 46% for rifabutin 150 mg daily plus LPV/r and 52%
for rifabutin 150 mg tiw plus LPV/r.
The Cmax of rifabutin 150 mg tiw with LPV/r was also
significantly lower when compared to the 150 mg daily
dose with LPV/r (P = 0.01) and the 300 mg daily dose
Table 1 Pharmacokinetic parameters for rifabutin and 25-O-desacetylrifabutin for each study treatment
Treatment period Rifabutin 300 mg Rifabutin 150 mg tiw plus LPV/r Rifabutin 150 mg daily plus LPV/r
Rifabutin (n = 14)
AUC0–24 (ng.h/mL) 3052.9 (2650.2-3431.5) 2307.5 (1767.5-3884.0) 4766.0 (3950.5-6099.5)
AUC0–48 (ng.h/mL) 6105.8 (5300.4-6863.0)* 3402.1 (2809.2-6092.0) 9532.0 (2238.2-22425.4)*
Cmax (ng/mL) 291.5 (250.0-377.0) 167.5 (87.8-294.0) 311.0 (258.0-376.0)
Tmax (h) 3.0 (3.0-4.0) 3.5 (3.0-5.0) 3.0 (3.0-4.0)
C0 (ng/mL) 59.0 (36.4-78.6) 49.1 (27.7-58.9) 176.5 (149.0-195.0)
Cmin 24 h (ng/mL) 60.7 (40.6-68.8) 70.7 (45.7-96.6) 133.0 (105.0-191.0)
Cmin 48 h (ng/mL) - 37.0 (26.6-70.0) -
CL/F (L/h) 98.3 (87.4-113.2) 65.2 (38.6-85.0) 31.5 (25.0-38.0)
AUC0–24 (ng.h/mL) (Rifabutin + Metabolite) 3402.3 (2900.3-3717.2) 3937.2 (2424.6-6772.7) 8753.0 (7771.7-11 505.0)
d-RBT (n = 14)
AUC0–24 (ng.h/mL) 273.3 (235.7-344.1) 1565.5 (1105.5-2567.3) 4118.0 (2678.2-5405.5)
AUC0–48 (ng.h/mL) 546.6 (471.4-688.2)
* 2318.2 (1722.9-4685.9) 8236.0 (5356.4-10811.0)*
Cmax (ng/mL) 32.5 (25.2-37.7) 77.2 (58.6-128) 236.5 (159.0-274.0)
Tmax (h) 3.0 (3.0-4.0) 5.0 (4.0-6.0) 4.0 (3.0-3.0)
C0 (ng/mL) 5.1 (2.7-6.6) 44.6 (31.7-68.9) 186.0 (115.0-232.0)
Cmin 24 h (ng/mL) 5.0 (3.4 -5.8 63.9 (42.7-101.0) 155.0 (53.6-206.0)
Cmin 48 h (ng/mL) - 35.4 (27.7-81.0) -
Parameters are median values (interquartile range).
*calculated by 2X AUC0–24.
RBT = rifabutin.
d-RBT =25-O-desacetylrifabutin.
LPV/r = lopinavir/ritonavir based ART.
tiw = three times per week.
AUC = area under the curve.
Cmax =maximum concentration in plasma.
Tmax = time at which maximum plasma attained.
CL/F = clearance.
C0 = pre-dose concentration.
Cmin = trough concentration.
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Cmax was 0.5 (0.4-0.6) for RBT 150 mg tiw compared
with RBT 300 mg and 0.5 (0.5-0.6) for RBT 150 mg
tiw compared with 150 mg daily. The median Cmin for
rifabutin 300 mg was 60.7 ng/mL (IQR, 40.6-68.8 ng/mL).
The Cmin values increased in the presence of LPV/r with
daily dosing of rifabutin but dropped significantly with the
tiw dose. Rifabutin clearance was significantly reduced in
the presence of LPV/r (p = 0.001 for daily and p = 0.002 tiw
rifabutin dosing) compared to 300 mg rifabutin given
alone.
Without lopinavir, d-RBT concentrations were 11%
of the parent drug. Plasma d-RBT concentrations in-
creased 5-fold with tiw rifabutin dosing and 15-fold
with daily doses of rifabutin (Figure 3). The total anti-
microbial moiety (combined AUC0–24 of rifabutin and
metabolite) for rifabutin at 150 mg tiw with ART was
1.2 times greater than for 300 mg rifabutin and 2.6
times less than for 150 mg daily with ART.Lopinavir pharmacokinetic analysis
Lopinavir pharmacokinetic measures are shown in Table 3
and Figure 4. Median lopinavir trough (C0) concentrations
were above the recommended lower limit for ART-naïve
patients of 1 μg/ [23]. Although there was a trend to higher
lopinavir concentrations with the once daily dosing of rifa-
butin, the differences in AUC0–12 and Cmax between the
two doses were not significant. Double peaks were ob-
served in the individual lopinavir concentration-time pro-
files with both doses of rifabutin.
Response to TB/HIV treatment
Three patients were culture positive after two months of
tuberculosis therapy and none culture positive at the
end of therapy. The mean final CD4+ count at the end of
tuberculosis therapy was 253.8 (42.4) cells/mm3, and sig-
nificantly higher (p = 0.03) than baseline. The mean (SD)
viral load dropped significantly (p < 0.001) by 2.7 log10
copies and 8 patients had viral loads < 500 copies/ml.
Figure 2 Rifabutin median concentration-time profiles. Median rifabutin (RBT) concentrations for the three pharmacokinetic evaluations in 14
patients. The orange line corresponds to the dosing of RBT at 300 mg without ART; the blue line to RBT dosing at 150 mg tiw with ART and the
purple line to dosing with 150 mg of RBT daily with ART. The bars represent interquartile range (IQR).
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Adverse events (AE) were analyzed for all sixteen patients.
Rifabutin was well tolerated at all doses and there was only
one withdrawal because of an adverse event (uveitis).
There were two serious adverse events (bacterial meningi-
tis and pyelonephritis), both considered unrelated to rifa-
butin by the study team. Grade 2 uveitis occurred in one
patient after 1 month of rifabutin, coinciding with the start
of ART, and resolved with no sequelae after withdrawal of
medication. Her AUC0–24 and Cmax values for rifabutin
were within the interquartile range. The commonest la-
boratory AE was neutropenia. Grade 3 neutropenia oc-
curred on 7 occasions in 5 patients (Table 4). There were
2 grade 3 elevations in transaminases and amylase. There
were no grade 4 laboratory events.Figure 3 25-O-desacetylrifabutin median concentration-time profiles.
pharmacokinetic evaluations in 14 patients. The bars represent interquartile
300 mg without ART; the red line to RBT dosing at 150 mg tiw with LPV/rDiscussion
The results of this study show that there are substantial
differences in the AUC0–24 of rifabutin obtained with the
two different dosing regimens in combination with LPV/r.
The daily dose of 150 mg resulted in a more than two fold
increase in the AUC0–24 when compared to the three
times a week dose. The difference between the two doses
was even greater when comparing the AUC0–48. There is a
lack of conventional efficacy data in support of a particular
dose or target pharmacokinetic parameter for rifabutin
[24], but there is convincing evidence that intermittent
rifamycin therapy is associated with tuberculosis relapse
and rifamycin resistance, especially in subjects with low
CD4 counts [17,18,25-27]. In TBTC study [18], TB-HIV
co-infected patients who had AUC0–24 < 4.5 μg.h/mL wereMedian 25-O-desacetylrifabutin (d-RBT) concentrations for the three
range (IQR). The blue line corresponds to the dosing of RBT at
based ART and the purple line to dosing with 150 mg of RBT daily.
Table 2 Geometric mean ratios of rifabutin and
25-O-desacetylrifabutin parameters with and without
antiretroviral therapy
GMR (90% CI)
RBT 150 mg tiw
with RBT 300 mg
daily
RBT 150 mg tiw
with RBT 150 mg
daily
RBT 150 mg daily
with RBT 300 mg
daily
AUC0–24 0.8 (0.7 – 0.9) 0.4 (0.5 – 0.5) 1.6 (1.4 – 1.9)
AUC0–48* 0.6 (0.5 – 0.7) 0.4 (0.4 – 0.4) n/a
Cmax(ng/mL) 0.5 (0.4 – 0.6) 0.5 (0.5 – 0.6) 1.0 (0.9 – 1.0)
C0(ng/mL) 0.7 (0.5 – 0.9) 0.2 (0.1 – 0.3) 3.4 (3.7 – 3.1)
Cmin24h(ng/mL) 1.2 (1.0 – 1.4) 0.5 (0.4 – 0.5) 2.7 (2.2 – 3.2)
*calculated by 2 times the AUC0–24 for the RBT 300 mg daily and RBT 150 mg
daily arms.
n/a – Not applicable.
GMR – Geometric mean ratio.
90% Cl – 90% confidence interval.
RBT 150 mg tiw – rifabutin dose of 150 mg three times per week (tiw) in
combination with lopinavir/ritonavir based ART and isoniazid.
RBT 150 mg daily – rifabutin dose of 150 mg daily in combination with
lopinavir/ritonavir based ART and isoniazid.
RBT 300 mg daily – rifabutin dose of 300 mg daily in combination with isoniazid.
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failed therapy 83% developed ARR as opposed to 33% who
had AUC’s above this threshold value. In this study,
71% patients on rifabutin 150 mg daily had AUC0–24
values >4.5 μg.h/mL compared to 14% on rifabutin tiw
dosing. Similarly the Cmin values of rifabutin 48 hours after
dosing tiw are significantly lower than the Cmin values for
300 mg daily and 150 mg daily. On the basis of prevention
of resistance our data support the guidelines that recom-
mend a dose of rifabutin 150 mg daily in combination with
protease inhibitors [28].
The AUC0–24 and Cmax of d-RBT were significantly
increased in the presence of LPV/r in keeping with pre-
vious treatment [29,30] and healthy volunteer studies
[11,31,32]. There were respective increases in exposureTable 3 Pharmacokinetic parameters for lopinavir for
each study treatment
Median (Interquartile range)
Parameter RBT 150 mg tiw
plus LVP/r
RBT 150 mg daily
plus LPV/r
AUC0–12 (μg.h/mL) 139.5 (103.8-163.9) 160.1 (129.1-181.9)
Cmax (ng/mL) 15.8 (12.9-17.1) 18.1 (14.5-19.6)
Tmax (h) 2.0 (2.0-3.0) 2.0 (2.0-3.0)
C0(μg/mL) 9.8 (3.5-14.0) 11.4 (9.9-15.2)
Cmin (μg/mL) 7.4 (4.5-10.0) 9.4 (7.2-11.6)
RBT = rifabutin.
LPV/r = lopinavir/ritonavir.
tiw = three times per week.
AUC = area under the curve.
Cmax =maximum concentration in plasma.
Tmax = time at which maximum plasma attained.
C0 = pre-dose concentration.
Cmin = trough concentration.to the metabolite of approximately 5- and 15-fold when
rifabutin 150 mg was given tiw or daily with LPV/r and
are probably due to the presence of ritonavir. Ritonavir is
a potent inhibitor of CYP3A4, which metabolizes d-RBT.
d-RBT is known to have significant anti-mycobacterial ac-
tivity and could contribute to the regimen efficacy [19].
These elevations of the d-RBT metabolite could led to an
increase in adverse drug reactions. We were unable to
show a significant association between plasma rifabutin
and d-RBT concentration and adverse events such as neu-
tropenia or elevated transaminases however the numbers
of patients are few and larger studies are required to estab-
lish the safety of the rifabutin 150 mg daily dose. It will also
be important to investigate the interaction of RBT in com-
bination with other antiretrovirals [33].
Although the currently recommended dose of rifabutin
for the treatment of pulmonary tuberculosis is 300 mg
daily there are few pharmacokinetic data from HIV in-
fected African tuberculosis patients treated with this
dose. The median rifabutin AUC0–24 and Cmax values from
this study are comparable to previous studies of rifabutin
300mg daily in HIV-infected patients [15,34-36]. The
pharmacodynamic-pharmacokinetic (PKPD) relationship
for rifabutin has not been comprehensively studied so it is
not clear how the reduced AUC of the 150 mg tiw dose
relative to the 300 mg dose without ART reported here
would impact on tuberculosis treatment outcomes. It is
still uncertain if Cmax or AUC is the critical pharmacody-
namic measure for rifamycins. Mitchison [37] and others
reported the Cmax/MIC to be the best PKPD measure
whereas subsequent murine and hollow fibre models
[38,39], and early bactericidal activity studies in humans
[40] found that the AUC0–24/MIC ratio was a superior
parameter.
Previous studies of the pharmacokinetic interaction of
rifabutin with LPV/r in HIV infected individuals have
mostly been small case series or involved an adaptive de-
sign in which only selected patients were exposed to the
higher dose of rifabutin [15,16,41]. One previous study
has reported on the rifabutin pharmacokinetics in com-
bination with LPV/r (Aluvia) but in patients initiating
rifabutin at the start of therapy [42]. This study was con-
ducted in Vietnam in a different population group but
also reported that the 150 mg tiw dose was potentially
sub therapeutic when compared to the 150 mg daily
dose or the 300 mg dose without ART. Similar to that
study we adopted a cross-over design in which all pa-
tients received 3 full pharmacokinetic assessments with
rifabutin alone and at two different rifabutin doses in com-
bination with ART allowing us to formally compare the
different dosing strategies and reduce intra-patient vari-
ability. However there are limitations to our study. Al-
though patients received rifabutin for a total of 18 weeks
our numbers are small so it is necessary to be cautious in
Figure 4 Median concentration-time profile of boosted lopinavir administered with two different doses of rifabutin. The median
lopinavir (LPV) concentrations for 14 patients administered 2 different concentrations of rifabutin (RBT). Blue line corresponds to a RBT dose of
150 mg daily and the purple line to 150 mg tiw. LPV/r corresponds to boosted lopinavir. The bars represent interquartile range (IQR).
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at the higher dose. We included immune-suppressed HIV
positive patient but not those with CD4 count less than
50, and it is conceivable that the pharmacokinetics and
tolerability of rifabutin may be different in the most highly
immune-suppressed group of patients.
Although the higher dose (150 mg daily) used in this
study resulted in rifabutin levels that reduce the risk of
resistance it is important to emphasis that the approxi-
mately 15 fold increase in the d-RBT metabolite might
result in an increase in adverse events. Neutropenia and
uveitis have previously been identified as severe adverse
events associated with the co-administration of rifabutin
with a CYP3A4 inhibitor [43-47]. A recent paediatric
clinical trial of rifabutin in combination with LPV/r wasTable 4 Timing of selected grade 3 laboratory adverse events
Subject AE Grade AE R
148 3 AST increased







242 3 AST increased
242 3 Amylase increased
250 3 Neutropenia
AE – adverse event.
RBT – rifabutin.
ARM – refers to the sequencing order of the rifabutin dosing in combination with A
tiw- three times per week.stopped due to a high frequency of grade 4 neutropenia
[14]. An advantage of this study is that patients remained
on study doses for sixteen weeks allowing a safety evalu-
ation to be made over a longer duration. In this study the
combinations of rifabutin and LPV/r were generally well
tolerated with no grade 4 toxicities apart from 2 clinical
serious adverse events reported by the study investigators
as unrelated to rifabutin. Neutropenia was a common
adverse event and has been reported predominantly in
previous studies on healthy volunteers, but there were no
grade 4 cases. Although there was a significant fall in the
neutrophil count during the course of the trial most
of this decline occurred in the first few weeks of rifabutin
therapy prior to the initiation of ART and we did not find
a significant association between neutropenia and plasmaBT dose at time of AE Arm Days on RBT
150 mg daily Low-High 106
150 mg daily Low-High 113
300 mg daily Low-High 29
300 mg daily Low-High 27
150 mg daily High-Low 57
150 mg tiw High-Low 112
300 mg daily High-Low 28
150 mg daily High-Low 53
150 mg tiw High-Low 96
150 mg tiw High-Low 119
150 mg daily Low-High 77
RT.
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common side effect of cotrimoxazole therapy in HIV- in-
fected patients [48] and all patients in the present study
were prescribed cotrimoxazole 960 mg daily as prophy-
laxis. The majority of the patients started cotrimoxazole at
enrollment and this would have contributed to the declin-
ing neutrophil count seen in this study. Uveitis occurred
only once in a participant who had been taking 300 mg
rifabutin and was not associated with high serum concen-
trations of drug suggesting it could have been HIV related
rather than drug related. However the number of patients
are small in this study so the safety of the 150 mg daily
rifabutin dose needs to be established in a larger cohort.
The activity of protease inhibitors is influenced by their
concentrations in plasma [49] therefore the pharmacokin-
etics of LPV/r were evaluated in the presence of rifabutin.
The median LPV/r AUC0–12, Cmax, C0 and C12 obtained in
this study when LPV/r was administered with two differ-
ent doses of rifabutin are consistent with historical control
data [50]. Secondary peaks were observed in the time-
concentration profiles of LPV/r, usually within 4 hours of
drug ingestion, similar to patterns observed in other stud-
ies. In both dosing arms, median LPV/r trough (C0) con-
centrations at steady state were above the recommended
lower limit for ART-naïve patients of 1 μg/mL [23] and
therapeutic LPV/r trough (C0) and Cmin (C12) concentra-
tions were achieved in all participants with both doses of
rifabutin.
Conclusions
In conclusion this study supports the recent change to
some guidelines for the dosing of rifabutin in combination
with LPV/r [28]. The high proportion of participants on
the 150 mg tiw arm who failed to achieve rifabutin concen-
trations that prevented the emergence of drug resistance
when the drug is dosed twice weekly is concerning.
Although escalating the rifabutin dose after therapeutic
drug monitoring is a viable option in resource rich settings,
it is impractical in many regions of the world where HIV
and TB are endemic. Our study was too small to address
all concerns about the toxicity of the higher dose rifabutin
with LPV/r, most notably the decrease in neutrophil count,
which requires further evaluation.
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